Essential Medicine Price Transparency Enforcement: Drug Administration Sanctions Four Domestic Pharma Majors Over Price Declaration Violations

Key Development

On August 4, 2026, the Drug Administration of Vietnam (DAV), operating under the Ministry of Health, formally issued four administrative penalty decrees targeting four major domestic pharmaceutical manufacturers for non-compliance with statutory price declaration regulations covering essential medicines.

Under the enforcement decrees, each pharmaceutical firm was assessed a monetary fine of 25 million VND. The four sanctioned enterprises and their respective infractions include:

1. Nam Ha Pharmaceutical JSC (Ninh Binh Province): Sanctioned for failing to submit required price declarations for the essential medicine Pelovime.

2. Domesco Medical Import Export JSC (Dong Thap Province): Sanctioned for failing to declare or submitting inaccurate price declarations across six essential medicines: Ciprofloxacin 500mg, Dosulvon 8mg, Amoxicillin 500mg, Cefalexin 500mg Caps, Dochicin 1mg, and Ofloxacin 200mg.

3. Minh Dan Pharmaceutical JSC (Ninh Binh Province): Sanctioned for submitting inaccurate commercial selling prices for the essential drug Cotrimoxazol 800/160.

4. Agimexpharm Pharmaceutical JSC (An Giang Province): Sanctioned for failing to submit price declarations across six essential medicines: Agifamcin 300, Agi-cotrim F, Agicipro, FUCAGI, Goutcolcin, and Agi-Ery 500.

Why It Matters

• Safeguarding Essential Medicine Pricing Structures: Essential medicines—encompassing primary-care broad-spectrum antibiotics (Amoxicillin, Ciprofloxacin, Cefalexin) and chronic pain/gout treatments (Dochicin, Goutcolcin)—represent core public health requirements. Enforcing mandatory price declarations prevents arbitrary price inflation and maintains market price stability.

• Statutory Late Penalty Rate (0.05% Daily Surcharge): Non-compliant firms must settle administrative fines within prescribed timelines. Failure to comply voluntarily triggers forced legal enforcement alongside an incremental late payment interest rate of 0.05% per day applied to outstanding balances.

• Strengthening Regulatory Compliance in Pharma: Price declaration is a mandatory statutory obligation under the Pharmaceutical Law, requiring commercial entities to notify regulatory authorities of anticipated retail and wholesale prices prior to market distribution. Issuing simultaneous sanctions against prominent manufacturers reinforces regulatory compliance across the industry.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, the August 4, 2026 enforcement action by the Drug Administration reflects a focused effort toward Drug Price Transparency Enforcement across Vietnam’s domestic market throughout 2026.

Sanctioned entities such as Domesco and Agimexpharm represent established, publicly traded pharmaceutical manufacturers operating modern GMP-certified facilities with extensive national distribution networks. Inaccuracies or omissions in declaring wholesale prices for widely prescribed essential antibiotics and therapies stem from two primary operational drivers:

1. Lagging Compliance Updates During API Price Volatility: Fluctuations in foreign Active Pharmaceutical Ingredient (API) import costs frequently prompt manufacturers to adjust commercial wholesale prices without concurrently updating official price declaration dockets with the DAV.

2. Commercial Pricing Discrepancies: Disconnects between declared price filings and actual commercial invoices allow distributors to manipulate trade discounts for retail pharmacy clients, distorting public price transparency.

While a 25 million VND fine represents a minor direct financial impact relative to corporate revenues, the associated Reputational Risk and increased regulatory scrutiny during public health insurance (VHI) hospital procurement tenders will compel pharmaceutical leadership teams to review internal legal compliance protocols.

Market Implications

1. Industry-Wide Audit of Drug Price Declarations: Peer pharmaceutical manufacturers and importers will likely conduct internal audits of essential drug price filings submitted to the DAV to ensure regulatory alignment.

2. Protecting Retail and Institutional Drug Pricing: Rigorous price declaration oversight ensures retail pharmacy chains (e.g., Long Chau, Pharmacity) and hospital procurement boards procure essential drugs at verified prices, protecting patient purchasing power.

3. Advancing Digital Governance in Pharmaceutical Tracking: The Drug Administration continues to digitize price declaration portals, enabling real-time cross-referencing between commercial sales data and official regulatory filings.

Regulatory Penalty Ledger: Essential Drug Price Violations

Sanctioned Enterprise	Primary Regulatory Infraction	Non-Compliant Essential Medicine Portfolio	Administrative Penalties & Enforcement
Nam Ha Pharma JSC	Omission of price declaration.	Pelovime	• Administrative fine: 25M VND. • Late surcharge: 0.05%/day if overdue.
Domesco Medical JSC	Omission / Inaccurate price filing.	6 Products: Ciprofloxacin 500mg, Dosulvon 8mg, Amoxicillin 500mg, Cefalexin 500mg, Dochicin 1mg, Ofloxacin 200mg.	• Administrative fine: 25M VND. • Late surcharge: 0.05%/day if overdue.
Minh Dan Pharma JSC	Inaccurate price declaration.	Cotrimoxazol 800/160	• Administrative fine: 25M VND. • Late surcharge: 0.05%/day if overdue.
Agimexpharm JSC	Omission of price declaration.	6 Products: Agifamcin 300, Agi-cotrim F, Agicipro, FUCAGI, Goutcolcin, Agi-Ery 500.	• Administrative fine: 25M VND. • Late surcharge: 0.05%/day if overdue.

Source: https://tuoitre.vn/phat-4-doanh-nghiep-duoc-vi-pham-ke-khai-gia-thuoc-thiet-yeu-100260804135957789.htm